UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors

European journal of cancer (1990), 2022-05, Vol.166, p.87-99

2022

Volltextzugriff (PDF)

Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes

Scientific reports, 2020-04, Vol.10 (1), p.7073-7073, Article 7073

2020

Volltextzugriff (PDF)

Residual pulmonary vascular obstruction and recurrence after acute pulmonary embolism. A single center cohort study

Thrombosis research, 2016-12, Vol.148, p.70-75

2016

Volltextzugriff (PDF)

Health-related quality of life analysis in ovarian cancer clinical trials involving PARP inhibitors: a critical methodological perspective

Quality of life research, 2022-12, Vol.31 (12), p.3331-3337

2022

Volltextzugriff (PDF)

A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors

International journal of cancer, 2019-08, Vol.145 (3), p.639-648

2019

Volltextzugriff (PDF)

Publisher Correction: Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes

Scientific reports, 2020-11, Vol.10 (1), p.19248-19248, Article 19248

2020

Volltextzugriff (PDF)

ASO Author Reflections: Bi-Directional Chemotherapy Using PIPAC Could Downstage Nonresectable Malignant Peritoneal Mesothelioma Patients to a Complete Resection

Annals of surgical oncology, 2022-03, Vol.29 (3), p.2114-2115

2022

Volltextzugriff (PDF)

An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring

Statistical methods in medical research, 2018-04, Vol.27 (4), p.1230-1239

2018

Volltextzugriff (PDF)

Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?

JNCI : Journal of the National Cancer Institute, 2018-03, Vol.110 (3), p.232-240

2018

Volltextzugriff (PDF)

The asymptotic distribution of the Net Benefit estimator in presence of right-censoring

Statistical methods in medical research, 2021-11, Vol.30 (11), p.2399-2412

2021

Volltextzugriff (PDF)

Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study

Annals of surgical oncology, 2022-03, Vol.29 (3), p.2104-2113

2022

Volltextzugriff (PDF)

ASO Author Reflections: Colorectal Cancer Patients with Peritoneal Metastases and Other Metastatic Sites Can Benefit from Radical Multifocal Treatment After Comprehensive Evaluation for Accurate Selection

Annals of surgical oncology, 2023-07, Vol.30 (7), p.4455-4456

2023

Volltextzugriff (PDF)

Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting

European journal of cancer (1990), 2019-11, Vol.121, p.192-201

2019

Volltextzugriff (PDF)

Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review

Journal of clinical oncology, 2013-11, Vol.31 (31), p.3957-3963

2013

Volltextzugriff (PDF)

Using intervention mapping to facilitate and sustain return-to work after breast cancer: protocol for the FASTRACS multicentre randomized controlled trial

BMC cancer, 2024-09, Vol.24 (1), p.1107-12, Article 1107

2024

Volltextzugriff (PDF)

Advances in the management of peritoneal malignancies

Nature reviews. Clinical oncology, 2022-11, Vol.19 (11), p.698-718

2022

Volltextzugriff (PDF)

Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors

European journal of cancer (1990), 2020-06, Vol.132, p.61-70

2020

Volltextzugriff (PDF)

Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trials

Nephrology, dialysis, transplantation, 2021-07, Vol.36 (7), p.1263-1271

2021

Volltextzugriff (PDF)

Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma

JAMA dermatology (Chicago, Ill.), 2018-01, Vol.154 (1), p.82

2018

Volltextzugriff (PDF)

The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma

Pancreas, 2019-02, Vol.48 (2), p.275-280

2019

Volltextzugriff (PDF)

Restricted Net Treatment Benefit in oncology

Journal of clinical epidemiology, 2024-06, Vol.170, p.111340, Article 111340

2024

Volltextzugriff (PDF)

Influence of Extraperitoneal Metastases on the Curative-Intent Management of Colorectal Peritoneal Metastases

Annals of surgical oncology, 2023-07, Vol.30 (7), p.4444-4454

2023

Volltextzugriff (PDF)

ASO Visual Abstract: Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study

Annals of surgical oncology, 2022-03, Vol.29 (3), p.2116-2117

2022

Volltextzugriff (PDF)

Breast cancer specialists' perspective on their role in their patients' return to work: A qualitative study

Scandinavian journal of work, environment & health, 2020-03, Vol.46 (2), p.177-187

2020

Volltextzugriff (PDF)

1 – 25 von 183

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(171)
Mit Volltextzugriff
(157)

Publikationsform

Artikel
(182)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors

Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes

The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review

Residual pulmonary vascular obstruction and recurrence after acute pulmonary embolism. A single center cohort study

Health-related quality of life analysis in ovarian cancer clinical trials involving PARP inhibitors: a critical methodological perspective

A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors

Publisher Correction: Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes

ASO Author Reflections: Bi-Directional Chemotherapy Using PIPAC Could Downstage Nonresectable Malignant Peritoneal Mesothelioma Patients to a Complete Resection

An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring

Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?

The asymptotic distribution of the Net Benefit estimator in presence of right-censoring

Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study

ASO Author Reflections: Colorectal Cancer Patients with Peritoneal Metastases and Other Metastatic Sites Can Benefit from Radical Multifocal Treatment After Comprehensive Evaluation for Accurate Selection

Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting

Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review

Using intervention mapping to facilitate and sustain return-to work after breast cancer: protocol for the FASTRACS multicentre randomized controlled trial

Advances in the management of peritoneal malignancies

Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors

Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trials

Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma

The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma

Restricted Net Treatment Benefit in oncology

Influence of Extraperitoneal Metastases on the Curative-Intent Management of Colorectal Peritoneal Metastases

ASO Visual Abstract: Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study

Breast cancer specialists' perspective on their role in their patients' return to work: A qualitative study

Suchergebnisse filtern